Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis

Chiara Fenoglio, Milena De Riz, Anna M. Pietroboni, Alberto Calvi, Maria Serpente, Sara M G Cioffi, Marina Arcaro, Emanuela Oldoni, Elio Scarpini, Daniela Galimberti

Research output: Contribution to journalArticlepeer-review

Abstract

MicroRNAs (miRNAs) have recently found to be dysregulated in serum from multiple sclerosis (MS) patients. Cell free circulating miR-15b, -23a and 223 levels were analyzed by Real Time PCR in a cohort consisting of 30 serum samples from Relapsing Remitting MS patients at baseline (T0) and after three, six, nine and twelve months (T1, T2, T3, T4) after starting the treatment. A down-regulation of miRNA levels in patients at T0 compared with controls was present (p < 0.001). MiRNA levels slightly increased at T1 and this trend reached the statistical significance at T2 vs T0 and remains stable at T3 and T4. Our preliminary results suggest that aberrant levels of circulating miRNAs are recovered in fingolimod treated MS patients. Circulating miRNAs profiling could thus represent an easy detectable biomarker of disease and response to treatment.

Original languageEnglish
Pages (from-to)81-83
Number of pages3
JournalJournal of Neuroimmunology
Volume299
DOIs
Publication statusPublished - Oct 15 2016

Keywords

  • Biomarker
  • Fingolimod
  • MicroRNA
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this